A product made in Columbus reached a major milestone at the end of 2024. Ensure, a nutritional drink made by Abbott ...

Abbott Laboratories on Wednesday forecast 2025 profit that came in line with Wall Street estimates as it expects new device ...

The outlook and technical action suggest Abbott Laboratories (NYSE: ABT) will lead healthcare names like Johnson & Johnson ...

The company’s projected adjusted diluted EPS for 2025 is between $5.05 and $5.25, marking double-digit growth at the midpoint. Abbott’s first-quarter 2025 adjusted EPS is expected to be between $1.05 ...

The lawsuit accuses the formula maker of deceptively marketing the milks to make them seem like the next recommended step for toddlers.

Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...

For 2025, Abbott forecast organic sales growth of between 7.5% and 8.5%, as well as adjusted earnings per share of $5.05 to $5.25. Analysts expect $5.16 a share on $42 billion in sales.

Formulas marketed for toddlers are a burgeoning business, but pediatricians have long recommended against their use.

Analyst Lee Hambright of Bernstein maintained a Buy rating on Abbott Laboratories (ABT – Research Report), boosting the price target to ...

ABT gains a key position in point-of-care testing, focusing on Infectious Disease, Cardiometabolic & Informatics, Toxicology and Consumer Diagnostics.

Abbott has received an innovation award for Lingo, its first consumer biowearable over-the-counter device designed to support ...

Abbott has won an innovation award for Lingo, its first consumer biowearable over-the-counter device that helps people ...